• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/10/21 10:30:26 AM ET
    $XLRN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $XLRN alert in real time by email
    SC 13G/A 1 tv0119-acceleronpharmainc.htm SCHEDULE 13G/A acceleronpharmainc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 3)*

    Name of issuer:  Acceleron Pharma Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  00434H108

    Date of Event Which Requires Filing of this Statement: December 31, 2020

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  00434H108

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    39,703

    7.  SOLE DISPOSITIVE POWER

    4,946,487

    8.  SHARED DISPOSITIVE POWER

    82,091

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,028,578

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    8.35%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Acceleron Pharma Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    128 Sidney Street
    Cambridge, MA 02139

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    00434H108

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

    5,028,578

      (b) Percent of Class:

    8.35%

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  0

    (ii)  shared power to vote or direct to vote:  39,703

    (iii)  sole power to dispose of or to direct the disposition of:  4,946,487

    (iv)  shared power to dispose or to direct the disposition of:  82,091

    Comments:

     

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    Not applicable

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    See Attached Appendix A

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 8, 2021

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

     

     

    Appendix A

    Subsidiary:

    Vanguard Asset Management, Limited

    Vanguard Fiduciary Trust Company

    Vanguard Global Advisors, LLC

    Vanguard Group (Ireland) Limited

    Vanguard Investments Australia Ltd

    Vanguard Investments Canada Inc.

    Vanguard Investments Hong Kong Limited

    Vanguard Investments UK, Limited

    *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G

     

    Get the next $XLRN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XLRN

    DatePrice TargetRatingAnalyst
    10/7/2021$180.00Hold
    Jefferies
    10/4/2021Strong Buy → Market Perform
    Raymond James
    10/1/2021$180.00Overweight → Equal-Weight
    Morgan Stanley
    10/1/2021$150.00 → $180.00Overweight → Equal-Weight
    Barclays
    10/1/2021$173.00 → $180.00Outperform → Market Perform
    Cowen & Co.
    9/30/2021$168.00 → $180.00Buy → Neutral
    HC Wainwright & Co.
    9/30/2021$146.00 → $180.00Overweight → Neutral
    Piper Sandler
    9/30/2021$148.00 → $180.00Market Perform
    SVB Leerink
    More analyst ratings

    $XLRN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    April 28, 2021 - FDA Takes Action For Failure to Submit Required Clinical Trial Results Information to ClinicalTrials.Gov

    For Immediate Release: April 28, 2021 Statement From: Statement Author Leadership Role Acting Commissioner of Food and Drugs - Food and Drug Administration Janet Woodcock M.D. Being transparent about the results of completed clinical trials enables important a

    4/28/21 1:06:44 PM ET
    $XLRN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $XLRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Zakrzewski Joseph S closing all direct ownership in the company to cover withholding tax

    4 - ACCELERON PHARMA INC (0001280600) (Issuer)

    11/22/21 9:12:32 AM ET
    $XLRN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4: Malik Kemal closing all direct ownership in the company (withholding obligation)

    4 - ACCELERON PHARMA INC (0001280600) (Issuer)

    11/22/21 9:11:36 AM ET
    $XLRN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4: Hite Christopher closing all direct ownership in the company to satisfy withholding tax

    4 - ACCELERON PHARMA INC (0001280600) (Issuer)

    11/22/21 9:10:42 AM ET
    $XLRN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $XLRN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Qiming Venture Partners USA Announces $260 Million US Healthcare Fund III and Addition of New Partner, Isaac Ciechanover

    Fund III will be invested in early-stage therapeutics and healthcare technology companies Qiming Venture Partners USA (Qiming US), a leading US healthcare investment firm, today announced the closing of its third fund, raising $260 million in an oversubscribed fundraise with strong support from new and existing investors. Qiming US will continue to execute on the same strategy as previous funds, deploying Fund III in early-stage therapeutics and healthcare technology companies in the US and EU that aim to improve patient outcomes and address unmet medical needs. "We are incredibly proud of the entrepreneurs and healthcare innovations we have supported in just a few short years, and we are

    6/2/22 8:00:00 AM ET
    $AGIO
    $ARRY
    $ATRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Miscellaneous manufacturing industries
    Consumer Discretionary

    Merck Completes Acquisition of Acceleron Pharma Inc.

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the successful completion of the acquisition of Acceleron Pharma Inc. (NASDAQ:XLRN). "This is an important and strategic opportunity for our company to continue growing our cardiovascular portfolio and pipeline, that builds on our long and proud legacy in cardiovascular disease and further bolsters our business development strategy," said Rob Davis, chief executive officer and president, Merck. "Fueled by Acceleron's groundbreaking research, we are excited to explore the opportunities and possibilities ahead to reach even more patients by addressing this critical health need." Acceleron is focused on harn

    11/22/21 6:45:00 AM ET
    $MRK
    $XLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, Astros Merger Sub, Inc., for all of the outstanding shares of common stock of Acceleron Pharma Inc. (NASDAQ:XLRN), at a purchase price of $180 per share in cash, without interest and less applicable tax withholding. As of the tender offer expiration at 5:00 p.m., Eastern Time, on Nov. 19, 2021, 38,752,614 shares of common stock of Acceleron were validly tendered and not withdrawn from the tender offer, representing approximately 63.3% of the total number of Acceleron's outstanding shares. All such shares have been accepted for payment

    11/19/21 6:06:00 PM ET
    $MRK
    $XLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $XLRN
    SEC Filings

    View All

    SEC Form 15-12B filed by Acceleron Pharma Inc.

    15-12B - ACCELERON PHARMA INC (0001280600) (Filer)

    12/2/21 9:00:53 AM ET
    $XLRN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Acceleron Pharma Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - ACCELERON PHARMA INC (0001280600) (Filer)

    11/22/21 8:52:10 AM ET
    $XLRN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 25-NSE filed by Acceleron Pharma Inc.

    25-NSE - ACCELERON PHARMA INC (0001280600) (Subject)

    11/22/21 8:41:23 AM ET
    $XLRN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $XLRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Acceleron Pharma with a new price target

    Jefferies initiated coverage of Acceleron Pharma with a rating of Hold and set a new price target of $180.00

    10/7/21 5:00:35 AM ET
    $XLRN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Acceleron Pharma downgraded by Raymond James

    Raymond James downgraded Acceleron Pharma from Strong Buy to Market Perform

    10/4/21 7:15:08 AM ET
    $XLRN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Acceleron Pharma downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Acceleron Pharma from Overweight to Equal-Weight and set a new price target of $180.00

    10/1/21 12:38:51 PM ET
    $XLRN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $XLRN
    Financials

    Live finance-specific insights

    View All

    Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders

    Remains Opposed to Sale of Acceleron to Merck at Current Price and Plans Not to Tender Its Shares Believes Company Has Strong Momentum and Continuing as Standalone Entity is Superior Path to a Transaction at the Proposed Price, Particularly with Major Value Inflection Point Coming from Phase 3 Data Outlines Alternatives by Which Acceleron Could Maximize Shareholder Value as Independent Company, Including by Monetizing Royalties Ready and Willing to Assist with Change in Board Composition to Better Position Company for Go-Forward Strategy Avoro Capital Advisors ("Avoro"), a long-term and collaborative investor in life sciences and biotechnology companies, beneficially owns approximately

    10/28/21 8:00:00 AM ET
    $MRK
    $XLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Bristol Myers Squibb Reports Second Quarter Financial Results for 2021

    Reports Second Quarter Revenues of $11.7 Billion, an Increase of 16% YoY, or 13% When Adjusted for Foreign Exchange Posts Second Quarter Earnings Per Share of $0.47 and Non-GAAP EPS of $1.93 Delivers Strong Commercial Performance, Including Opdivo's Return to Growth and Momentum across New Product Portfolio Achieves Significant Regulatory and Clinical Milestones across Product Pipeline Further Strengthens Pipeline through Disciplined Business Development Agreements, including with Agenus and Eisai Adjusts GAAP and Reaffirms Non-GAAP EPS Guidance for 2021 Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2021, which reflect robust product sales, co

    7/28/21 6:59:00 AM ET
    $XLRN
    $BMY
    $BLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $XLRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Acceleron Pharma Inc. (Amendment)

    SC 13D/A - ACCELERON PHARMA INC (0001280600) (Subject)

    11/24/21 3:48:08 PM ET
    $XLRN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Acceleron Pharma Inc. (Amendment)

    SC 13G/A - ACCELERON PHARMA INC (0001280600) (Subject)

    11/10/21 12:24:23 PM ET
    $XLRN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by Acceleron Pharma Inc.

    SC 13D - ACCELERON PHARMA INC (0001280600) (Subject)

    10/5/21 12:30:20 PM ET
    $XLRN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care